gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

WAP four-disulfide core domain 2

HE4, WFDC2, WAP four-disulfide core domain 2
This gene encodes a protein that is a member of the WFDC domain family. The WFDC domain, or WAP Signature motif, contains eight cysteines forming four disulfide bonds at the core of the protein, and functions as a protease inhibitor in many family members. This gene is expressed in pulmonary epithelial cells, and was also found to be expressed in some ovarian cancers. The encoded protein is a small secretory protein, which may be involved in sperm maturation. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CA-125, CAN, HAD, fibrillin-1, AGE
Papers using HE4 antibodies
Biosensors for detection of pathogenic bacteria
Xi Mingrong et al., In International Journal of Nanomedicine, 1998
... Mouse monoclonal anti-HE4 antibody (anti-HE4) and standard HE4 were obtained from Abnova (Taiwan, China) ...
Papers on HE4
Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?
Menkiszak et al., Szczecin, Poland. In Tumour Biol, Feb 2016
UNASSIGNED: After several years of research, HE4 was found to be characterized by slightly worse sensitivity but significantly higher specificity as compared with CA125.
Human epididymis protein 4 expression positively correlated with miR-21 and served as a prognostic indicator in ovarian cancer.
Gao et al., Fu'an, China. In Tumour Biol, Feb 2016
Human epididymis protein 4 (HE4) is a useful biomarker for ovarian cancer when either used alone or in combination with carbohydrate antigen 125 (CA125).
Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
Kyung et al., South Korea. In J Korean Med Sci, Dec 2015
This study is a multi-center clinical study, which aimed to compare CA125, HE4, and risk of ovarian malignancy algorithm (ROMA) in predicting epithelial ovarian cancer of Korean women with a pelvic mass.
Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case-control study.
Bałajewicz-Nowak et al., Kraków, Poland. In Taiwan J Obstet Gynecol, Dec 2015
OBJECTIVE: To evaluate the clinical significance of the combination of cancer antigen-125 (CA-125), human epididymis protein 4 (HE4), and progesterone for the identification of ovarian masses in patients with suspected early stage ovarian cancer (OC).
Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.
Azzoli et al., Sydney, Australia. In Plos One, Dec 2015
METHODS: Serum NSE, CYFRA 21-1, ProGRP, SCC-Ag, TIMP1, and HE4 by ELISA-based proteomic assays were prospectively collected from consecutive patients with stage IV NSCLC.
Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.
Tian et al., Beijing, China. In Medicine (baltimore), Dec 2015
Risk of Ovarian Malignancy Algorithm (ROMA) combing human epididymis secretary protein 4 (HE4) and CA125 showed better diagnostic accuracy for epithelial ovarian cancer (EOC) when compared with HE4 or CA125 alone; however, other studies showed no or worse diagnostic accuracy.
The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer.
Li et al., Zhengzhou, China. In Clin Transl Oncol, Aug 2015
Human epididymis protein 4 (HE4) has been regarded as a new powerful biomarker in diagnosis of EOC; we hope to obtain system knowledge of HE4 and understand the role of HE4 in diagnosis of epithelial ovarian cancer (EOC).
HE4 in the differential diagnosis of ovarian masses.
Anastasi et al., Roma, Italy. In Clin Chim Acta, Jul 2015
Recently, HE4 has been proposed as emerging biomarker in the differential diagnosis of adnexal masses and in the early diagnosis of ovarian cancer.
Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.
Zhang et al., Zhengzhou, China. In Expert Rev Mol Diagn, Jun 2015
CA125, p53 and HE4 were the most frequently tested TAAs in OC.
[Ca-125 in diagnosis and monitoring of patients with ovarian cancer].
Ivanov et al., In Akush Ginekol (sofiia), 2014
Ca-125 and HE4 are both validated serum markers for differential diagnose of pelvic masses.
The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects.
Scatena et al., Roma, Italy. In Adv Exp Med Biol, 2014
Increased clinical performance, in terms of better sensitivity and specificity in identifying epithelial ovarian cancer relapse, has been obtained by combined use of CA 125 with HE4, another ovarian cancer marker recently introduced in clinical use.
Value of serum marker HE4 in pulmonary carcinoma diagnosis.
Sun et al., Yancheng, China. In Int J Clin Exp Med, 2014
Serum levels of carcinoma embryonic antigen (CEA), cytokeratin protein fragment 21-1 (CYFRA21-1), neuron-specific enolase (NSE), and human epididymis protein 4 (HE4) were detected using electrochemiluminescence.
Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis.
Kalluri et al., Boston, United States. In Nat Med, 2013
Using a new genetic mouse model to track and isolate myofibroblasts, we performed gene expression profiling followed by biological validation to identify HE4 (encoding human epididymis protein 4, also known as WAP 4-disulfide core domain-2 or Wfdc2) as the most upregulated gene in fibrosis-associated myofibroblasts.
Serum HE4 as a diagnostic and prognostic marker for lung cancer.
Naka et al., Ibaraki, Japan. In Tumour Biol, 2012
Findings suggest that serum epididymis protein 4 (HE4) is a potential diagnostic and prognostic marker for lung cancer.
HE4 is an independent prognostic marker in endometrial cancer patients.
Widschwendter et al., Innsbruck, Austria. In Gynecol Oncol, 2012
Pretherapeutic serum HE4 levels alone and in combination with CA125 are an independent prognostic marker in endometrial cancer patients.
Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
Gao et al., Beijing, China. In Int J Gynecol Cancer, 2012
adds valuable information to CA125 in identifying patients with epithelial ovarian cancer from those with benign pelvic disease
Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility.
Guo et al., Shanghai, China. In Biochem Biophys Res Commun, 2012
these results provide evidence of the cellular and molecular mechanisms that may underlie the motility-promoting role of HE4 in epithelial ovarian cancer progression.
[HE4--a new tumor marker for ovarian cancer].
Andreeva et al., In Akush Ginekol (sofiia), 2010
HE4 is vastly more specific and early-phase diagnosed tumor marker in cases with ovarian cancer.
Development of a multimarker assay for early detection of ovarian cancer.
Lokshin et al., Pittsburgh, United States. In J Clin Oncol, 2010
The four-biomarker panel providing the highest diagnostic power of 86% sensitivity (SN) for early-stage and 93% SN for late-stage ovarian cancer at 98% specificity (SP) was comprised of CA-125, HE4, CEA, and VCAM-1.
Proteins with whey-acidic-protein motifs and cancer.
Tremblay et al., Québec, Canada. In Lancet Oncol, 2006
Most notably, the genes coding for elafin, antileukoproteinase 1 (previously called secretory leucocyte proteinase inhibitor, SLPI), WAP four disulphide core domain protein 1 (previously called prostate stromal protein 20 kDa, PS20), and WAP four disulphide core domain protein 2 (previously called major human epididymis-specific protein E4, HE4), have been identified as candidate molecular markers for several cancers.
share on facebooktweetadd +1mail to friends